A combination of anti-PD-1 therapy and apatinib successfully treated a patient with EGFR mutation-negative advanced lung adenocarcinoma: A case report.

Abstract excerpt

Here, we report the case of a patient with advanced lung adenocarcinoma with negative driver genes, who benefited from treatment with anti-programmed cell death-1 (anti-PD-1) therapy combined with a low dose of apatinib. From February 2020, the patient was treated with camrelizumab combined with pemetrexed disodium. The treatment regimen was adjusted to camrelizumab combined with a low dose of apatinib every 3...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Adenocarcinoma of Lung
• Share to ErbB Receptors